7709 - Lymphogranulomatosis (Hodgkin's disease)

Old Code

New Code

7709 - Hodgkin's disease

Old Rating Criterion 1

7709 Effective July 2, 1985 to October 23, 1995

7709 - Lymphogranulomatosis (Hodgkin's disease)	Rating
An evaluation of 100 percent is granted for acute, malignant disease or chronic types with frequent episodes of high and progressive fever, or febrile episodes with only short remissions, generalized edema, ascites, pleural effusion, or severe anemia with marked general weakness. The 100 percent evaluation is continued for one year following cessation of antineoplastic therapy.	100
An evaluation of 60 percent is granted if the record shows: general muscular weakness with loss of weight and chronic anemia; secondary pressure symptoms, such as marked dyspnea, edema with pains and weakness of an extremity; or other evidence of severe impairment of general health. A higher evaluation of 100 percent is not warranted unless there is evidence of acute, malignant disease or chronic types with frequent episodes of high and progressive fever, or febrile episodes with only short remissions, generalized edema, ascites, pleural effusion, or severe anemia with marked general weakness. The 100 percent evaluation is continued for one year following cessation of antineoplastic therapy.	60
An evaluation of 30 percent is assigned if there is a showing of occasional low-grade fever, mild anemia, fatigability, or pruritus. A higher evaluation of 60 percent is not warranted unless evidence demonstrates general muscular weakness with loss of weight and chronic anemia; secondary pressure symptoms, such as marked dyspnea, edema with pains and weakness of an extremity; or other evidence of severe impairment of general health.	30

Old Rating Criterion 2

7709 Effective October 23, 1995 to December 9, 2018

7709 - Hodgkin's disease	Rating
With active disease or during a treatment phase	100
Note: The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of 38 CFR 3.105(e). If there has been no local recurrence or metastasis, rate on residuals.

7709 - Hodgkin's disease

Rating

With active disease or during a treatment phase

100

Note: The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of 38 CFR 3.105(e). If there has been no local recurrence or metastasis, rate on residuals.